Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis
- PMID: 20191031
- PMCID: PMC2826733
- DOI: 10.3346/jkms.2010.25.3.348
Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis
Abstract
The aim of this study was to analyze the relationship between serum pro-hepcidin concentration and the anemia profiles of rheumatoid arthritis (RA) and to estimate the pro-hepcidin could reflect the disease activity of RA. RA disease activities were measured using Disease Activity Score 28 (DAS28), tender/swollen joint counts, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Anemia profiles such as hemoglobin, iron, total iron binding capacity (TIBC), ferritin, and transferrin levels were measured. Serum concentration of pro-hepcidin, the prohormone of hepcidin, was measured using enzyme-linked immunosorbent assay (ELISA). Mean concentration of serum pro-hepcidin was 237.6+/-67.9 ng/mL in 40 RA patients. The pro-hepcidin concentration was correlated with rheumatoid factor, CRP, ESR, and DAS28. There was a significant correlation between pro-hepcidin with tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6. The pro-hepcidin concentration was significantly higher in the patients with active RA (DAS28>5.1) than those with inactive to moderate RA (DAS28< or =5.1). However, the pro-hepcidin concentration did not correlate with the anemia profiles except hemoglobin level. There was no difference of pro-hepcidin concentration between the patients with anemia of chronic disease and those without. In conclusion, serum concentration of pro-hepcidin reflects the disease activity, regardless of the anemia states in RA patients, thus it may be another potential marker for disease activity of RA.
Keywords: Anemia; Arthritis, Rheumatoid; Hepcidin; Prohepcidin.
Similar articles
-
Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus.Inflammation. 2008 Jun;31(3):146-53. doi: 10.1007/s10753-008-9060-8. Epub 2008 Feb 16. Inflammation. 2008. PMID: 18278547
-
Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis.J Rheumatol. 2011 Oct;38(10):2153-9. doi: 10.3899/jrheum.110339. Epub 2011 Sep 1. J Rheumatol. 2011. PMID: 21885483
-
Interleukin-1 receptor antagonist gene polymorphism and hepcidin in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity.IUBMB Life. 2013 Oct;65(10):883-8. doi: 10.1002/iub.1205. Epub 2013 Sep 6. IUBMB Life. 2013. PMID: 24014495
-
Rheumatoid anemia.Joint Bone Spine. 2011 Mar;78(2):131-7. doi: 10.1016/j.jbspin.2010.05.017. Epub 2010 Sep 18. Joint Bone Spine. 2011. PMID: 20851655 Review.
-
Serum IL-37 Level Is Associated with Rheumatoid Arthritis and Disease Activity: A Meta-Analysis.Biomed Res Int. 2021 Feb 5;2021:6653439. doi: 10.1155/2021/6653439. eCollection 2021. Biomed Res Int. 2021. Retraction in: Biomed Res Int. 2023 Nov 29;2023:9827814. doi: 10.1155/2023/9827814. PMID: 33628802 Free PMC article. Retracted.
Cited by
-
Serum hepcidin level and rheumatoid arthritis disease activity.Eur J Rheumatol. 2018 Dec 19;6(2):76-80. doi: 10.5152/eurjrheum.2018.18114. Print 2019 Apr. Eur J Rheumatol. 2018. PMID: 31365340 Free PMC article.
-
Rheumatoid factor and its interference with cytokine measurements: problems and solutions.Arthritis. 2011;2011:741071. doi: 10.1155/2011/741071. Epub 2011 Jun 22. Arthritis. 2011. PMID: 22046523 Free PMC article.
-
Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.Arthritis Res Ther. 2013 Oct 2;15(5):R141. doi: 10.1186/ar4323. Arthritis Res Ther. 2013. PMID: 24286116 Free PMC article. Clinical Trial.
-
Hepcidin: A useful marker in chronic obstructive pulmonary disease.Ann Thorac Med. 2012 Jan;7(1):31-5. doi: 10.4103/1817-1737.91562. Ann Thorac Med. 2012. PMID: 22347348 Free PMC article.
-
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry.Arthritis Res Ther. 2022 Dec 21;24(1):276. doi: 10.1186/s13075-022-02955-y. Arthritis Res Ther. 2022. PMID: 36544236 Free PMC article.
References
-
- Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):50S–57S. - PubMed
-
- Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol. 2002;31:251–259. - PubMed
-
- Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica. 1997;82:375–381. - PubMed
-
- Vreugdenhil G, Lowenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest. 1992;22:488–493. - PubMed
-
- Ganz T. Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol. 2005;18:171–182. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous